Skip navigation
Skip navigation

Histone deacetylase inhibitor panobinostat induces clinical responses with associated alterations in gene expression profiles in cutaneous T-cell lymphoma

Ellis, Leigh; Pan, Yan; Smyth, Gordon K.; George, Daniel J.; McCormack, Chris; Williams-Truax, Roxamme; Mita, Monica; Beck, Joachim; Burris, Howard; Ryan, Gail; Atadja, Peter; Butterfoss, Dale; Johnstone, Ricky


Purpose: Histone deacetylase inhibitors can alter gene expression and mediate diverse antitumor activities. Herein, we report the safety and activity of the histone deacetylase inhibitor panobinostat (LBH589) in cutaneous T-cell lymphoma (CTCL) and identify genes commonly regulated by panobinostat. Experimental Design: Panobinostat was administered orally to patients with CTCL on Monday, Wednesday, and Friday of each week on a 28-day cycle. A dose of 30 mg was considered excessively toxic, and...[Show more]

CollectionsANU Research Publications
Date published: 2008
Type: Journal article
Source: Clinical Cancer Research
DOI: 10.1158/1078-0432.CCR-07-4262


File Description SizeFormat Image
01_Ellis_Histone_deacetylase_inhibitor_2008.pdf881.57 kBAdobe PDF    Request a copy

Items in Open Research are protected by copyright, with all rights reserved, unless otherwise indicated.

Updated:  19 May 2020/ Responsible Officer:  University Librarian/ Page Contact:  Library Systems & Web Coordinator